WallStreetZenWallStreetZen

NASDAQ: VOR
Vor Biopharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for VOR

Based on 6 analysts offering 12 month price targets for Vor Biopharma Inc

Min Forecast
$18.00+25.61%
Avg Forecast
$36.50+154.71%
Max Forecast
$50.00+248.92%

Should I buy or sell VOR stock?

Based on 6 analysts offering ratings for Vor Biopharma Inc.

Strong Buy
Strong Buy
4 analysts 66.67%
Buy
1 analysts 16.67%
Hold
1 analysts 16.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although VOR's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates VOR as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their VOR stock forecasts and price targets.

VOR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-18
lockedlocked$00.00+00.00%2026-05-14
lockedlocked$00.00+00.00%2026-03-30
lockedlocked$00.00+00.00%2026-03-19
lockedlocked$00.00+00.00%2026-01-09
JP Morgan
Top 5%
96
Strong BuyMaintains$40.00+165.96%2025-12-19

1 of 1

Forecast return on equity

Is VOR forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is VOR forecast to generate an efficient return on assets?

Company
-21.6%
Industry
29.42%
VOR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VOR earnings per share forecast

What is VOR's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$4.39
Avg 2 year Forecast
-$3.51
Avg 3 year Forecast
-$3.96

VOR revenue forecast

What is VOR's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$29.1M

VOR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VOR$15.04$36.50+142.69%Strong Buy
SPRY$8.23N/AN/A
CTMX$3.76$12.88+242.42%Strong Buy
GERN$1.26N/AN/A
LBRX$28.00$40.33+44.05%Strong Buy
View Top Biotech Stocks

Vor Biopharma Stock Forecast FAQ

Is Vor Biopharma Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: VOR) stock is to Strong Buy VOR stock.

Out of 6 analysts, 4 (66.67%) are recommending VOR as a Strong Buy, 1 (16.67%) are recommending VOR as a Buy, 1 (16.67%) are recommending VOR as a Hold, 0 (0%) are recommending VOR as a Sell, and 0 (0%) are recommending VOR as a Strong Sell.

If you're new to stock investing, here's how to buy Vor Biopharma stock.

What is VOR's earnings growth forecast for 2026-2028?

(NASDAQ: VOR) Vor Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.38%.

Vor Biopharma's earnings in 2026 is -$883,080,000.On average, 10 Wall Street analysts forecast VOR's earnings for 2026 to be -$237,708,024, with the lowest VOR earnings forecast at -$399,859,261, and the highest VOR earnings forecast at -$126,307,279. On average, 10 Wall Street analysts forecast VOR's earnings for 2027 to be -$189,921,499, with the lowest VOR earnings forecast at -$237,366,653, and the highest VOR earnings forecast at -$141,100,024.

In 2028, VOR is forecast to generate -$214,711,538 in earnings, with the lowest earnings forecast at -$348,458,538 and the highest earnings forecast at -$118,341,955.

What is VOR's revenue growth forecast for 2026-2028?

(NASDAQ: VOR) Vor Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.05%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.75%.

Vor Biopharma's revenue in 2026 is $0.On average, 7 Wall Street analysts forecast VOR's revenue for 2026 to be $0, with the lowest VOR revenue forecast at $0, and the highest VOR revenue forecast at $0. On average, 7 Wall Street analysts forecast VOR's revenue for 2027 to be $0, with the lowest VOR revenue forecast at $0, and the highest VOR revenue forecast at $0.

In 2028, VOR is forecast to generate $1,578,597,155 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $5,088,758,267.

What is VOR's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: VOR) forecast ROA is -21.6%, which is lower than the forecast US Biotechnology industry average of 29.42%.

What is VOR's Price Target?

According to 6 Wall Street analysts that have issued a 1 year VOR price target, the average VOR price target is $36.50, with the highest VOR stock price forecast at $50.00 and the lowest VOR stock price forecast at $18.00.

On average, Wall Street analysts predict that Vor Biopharma's share price could reach $36.50 by May 18, 2027. The average Vor Biopharma stock price prediction forecasts a potential upside of 142.69% from the current VOR share price of $15.04.

What is VOR's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: VOR) Vor Biopharma's current Earnings Per Share (EPS) is -$70.13. On average, analysts forecast that VOR's EPS will be -$4.39 for 2026, with the lowest EPS forecast at -$7.38, and the highest EPS forecast at -$2.33. On average, analysts forecast that VOR's EPS will be -$3.51 for 2027, with the lowest EPS forecast at -$4.38, and the highest EPS forecast at -$2.60. In 2028, VOR's EPS is forecast to hit -$3.96 (min: -$6.43, max: -$2.18).

What is VOR's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: VOR) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.